Empowered Patient Podcast

Dr. Calum Yacoubian, the Director of NLP Healthcare Strategy for IQVIA, is applying clinical natural language processing to take complex, unstructured healthcare data and turn it into structured and searchable information. In a value-based care environment, clinical NLP can augment manual work by nurses, clinical coders, and clinicians to identify relevant, often unstructured information at the right time for specific patients, and payers to undergo chart review for risk adjustment.

Calum explains, "Within healthcare, data and information are hugely fragmented. There was a HIMSS report in 2020 that said the average healthcare system in the U.S. has 15 disparate EMR systems it is pulling data from. Going back to your first question, the 360-degree view of a patient is about using as much data as available to understand patients and the populations they exist in. If it's difficult to access and make the most of the data. That's the first and probably one of the biggest barriers that we have in healthcare, this disparate data that exists in the ecosystem, and the multiple different formats that it exists in."

"In the healthcare setting, huge amounts of clinical information is in text form, either dictated and transcribed or typed directly by clinicians into the free text boxes. These have become the kind of dumping ground for much clinically relevant information in a clinical setting. When we think of that data, clinical NLP, which is specifically my focus, we are able to look into that data to understand the nuance of that information and to pull out information and data in a structured format in a way the provider or the nurse or the physician or one of the other allied health professionals intended when they were interviewing the patient and documenting it in the medical record."

@IQVIA_global #IQVIA #ClinicalNLP #NLP #NaturalLanguageProcessing #RiskAssessment #ArtificialIntelligence #AI #ML #MachineLearning #Healthcare #HealthcareData #ValueBasedCare #PrecisionMedicine #PopulationHealth #SDoH #RareDiseases

IQVIA.com

Listen to the podcast here

Dr. Calum Yacoubian, the Director of NLP Healthcare Strategy for IQVIA, is applying clinical natural language processing to take complex, unstructured healthcare data and turn it into structured and searchable information. In a value-based care environment, clinical NLP can augment manual work by nurses, clinical coders, and clinicians to identify relevant, often unstructured information at the right time for specific patients, and payers to undergo chart review for risk adjustment.

Calum explains, "Within healthcare, data and information are hugely fragmented. There was a HIMSS report in 2020 that said the average healthcare system in the U.S. has 15 disparate EMR systems it is pulling data from. Going back to your first question, the 360-degree view of a patient is about using as much data as available to understand patients and the populations they exist in. If it's difficult to access and make the most of the data. That's the first and probably one of the biggest barriers that we have in healthcare, this disparate data that exists in the ecosystem, and the multiple different formats that it exists in."

"In the healthcare setting, huge amounts of clinical information is in text form, either dictated and transcribed or typed directly by clinicians into the free text boxes. These have become the kind of dumping ground for much clinically relevant information in a clinical setting. When we think of that data, clinical NLP, which is specifically my focus, we are able to look into that data to understand the nuance of that information and to pull out information and data in a structured format in a way the provider or the nurse or the physician or one of the other allied health professionals intended when they were interviewing the patient and documenting it in the medical record."

@IQVIA_global #IQVIA #ClinicalNLP #NLP #NaturalLanguageProcessing #RiskAssessment #ArtificialIntelligence #AI #ML #MachineLearning #Healthcare #HealthcareData #ValueBasedCare #PrecisionMedicine #PopulationHealth #SDoH #RareDiseases

IQVIA.com

Download the transcript here

Angela Fox is Head of Analytics at Bright.md which is an asynchronous telehealth solution bringing an audio-only virtual visit option to providers for them to treat patients with common low-acuity conditions. Staffing challenges, clinician burnout and increasing demand from an aging population are driving the acceptance of creative solutions to provide cost-effective, timely healthcare for patients.

Angela explains, "Through a patient's health system portal, they can get online and take a clinical interview. Then they answer several clinical questions about what care they're looking for, what care they're seeking that day. Then that's sent to a provider at their health system in an easy-to-review chart note. So the provider can review the chart note, make a diagnosis, and a treatment plan. This all happens completely within the electronic medical record."

"One of the key elements that we also include in our reporting is provider variation. And that kind of information about how productive providers are, which providers are treating more quickly, which providers need a little more time, can really help spark conversations within a health system and help them think about how to deploy their staff in the best possible way, how to be most efficient, how to make sure the quality is top notch."

@Brightmd_Health #AsynchronousCare #Telehealth #DataAnalytics #ProviderBurnout

Bright.md

Listen to the podcast here

Angela Fox is Head of Analytics at Bright.md which is an asynchronous telehealth solution bringing an audio-only virtual visit option to providers for them to treat patients with common low-acuity conditions. Staffing challenges, clinician burnout and increasing demand from an aging population are driving the acceptance of creative solutions to provide cost-effective, timely healthcare for patients.

Angela explains, "Through a patient's health system portal, they can get online and take a clinical interview. Then they answer several clinical questions about what care they're looking for, what care they're seeking that day. Then that's sent to a provider at their health system in an easy-to-review chart note. So the provider can review the chart note, make a diagnosis, and a treatment plan. This all happens completely within the electronic medical record."

"One of the key elements that we also include in our reporting is provider variation. And that kind of information about how productive providers are, which providers are treating more quickly, which providers need a little more time, can really help spark conversations within a health system and help them think about how to deploy their staff in the best possible way, how to be most efficient, how to make sure the quality is top notch."

@Brightmd_Health #AsynchronousCare #Telehealth #DataAnalytics #ProviderBurnout

Bright.md

Download the transcript here

Matthew Hedberg is the VP General Manager of Professional Services at Semcasting a data-as-a-service company working with health insurers, agents, CCOs, PPOs, hospital networks, and pharmaceutical and medical device manufacturers. Carrying a SOC 2 Type II certification, Semcasting is helping clients determine how to use the information they have and enhance that data to incorporate it into a digital program for patient outreach and education of targeted audiences.

Matthew explains, "There are significant timelines as well. Even if we are scoped to receive data for a particular project from a particular brand, it may take weeks or months to get the necessary additional approvals to receive certain levels of patient or member information for a particular project. This is just as an additional layer of safety and concern to make sure that patient data is protected and isn't circulating around amongst any players who aren't required to see it."

"One of the more specific tactical tools we developed back in 2018 was the idea of utilizing IP addresses as an advertising efficiency to reach patients, utilizing publication by Wi-Fi within the particular physician offices. What we realized, especially when we're looking at recruiting for clinical trials, is that this decision is necessarily incredibly complex to understand, even if a patient is wonderfully adept at researching their own healthcare condition. So, what we decided to attempt in there was how can we provide a certain message about the availability of a particular treatment to a patient but also allow them to do so in a window where they may be able to have a conversation with the physician about all of the complexities that may surround this particular decision."

@Semcasting #DigitalAds #ClinicalTrialRecruitment #TargetingPatients #PharmaceuticalAds #RareDiseases

semcasting.com

Listen to the podcast here

Matthew Hedberg is the VP General Manager of Professional Services at Semcasting a data-as-a-service company working with health insurers, agents, CCOs, PPOs, hospital networks, and pharmaceutical and medical device manufacturers. Carrying a SOC 2 Type II certification, Semcasting is helping clients determine how to use the information they have and enhance that data to incorporate it into a digital program for patient outreach and education of targeted audiences.

Matthew explains, "There are significant timelines as well. Even if we are scoped to receive data for a particular project from a particular brand, it may take weeks or months to get the necessary additional approvals to receive certain levels of patient or member information for a particular project. This is just as an additional layer of safety and concern to make sure that patient data is protected and isn't circulating around amongst any players who aren't required to see it."

"One of the more specific tactical tools we developed back in 2018 was the idea of utilizing IP addresses as an advertising efficiency to reach patients, utilizing publication by Wi-Fi within the particular physician offices. What we realized, especially when we're looking at recruiting for clinical trials, is that this decision is necessarily incredibly complex to understand, even if a patient is wonderfully adept at researching their own healthcare condition. So, what we decided to attempt in there was how can we provide a certain message about the availability of a particular treatment to a patient but also allow them to do so in a window where they may be able to have a conversation with the physician about all of the complexities that may surround this particular decision."

@Semcasting #DigitalAds #ClinicalTrialRecruitment #TargetingPatients #PharmaceuticalAds #RareDiseases

semcasting.com

Download the transcript here

Dr. Tadd Lazarus is the Chief Medical Officer at Pictor, working on innovative diagnostic tests to provide answers to complicated clinical questions concerning the status of a patient's level of antibodies. From one specimen, their test can determine if the antibodies have been produced as a result of vaccinations or boosters and if the patient had the disease being tested for. Their mission is to help patients determine if they have effective antibody levels and are able to have the kind of response that will be protected them over time.

Tadd explains, "We develop innovative diagnostic solutions to enable more informed clinical decisions both in human and animal health. Specifically, we have a highly multiplexed platform that really changes the way antibodies are detected. As we know from COVID, antibodies are proteins that our body manufactures in response to infectious agents, except we detect them differently. We detect antibodies in an incredibly focused and what we call highly multiplexed manner, so that we have an incredibly sensitive and specific test. But moreover, it's able to detect multiple antibodies that the body produces for multiple infectious agents at one time. That's a very big change."

"One of the reasons why it is important to determine if vaccinations and boosters are effective is that there are antibodies that can be administered to patients intravenously if those patients are determined not to have a clinically significant antibody response to vaccinations/boosters and/or infection. And those formulations are getting tweaked now for more predominant strains, so making sure that they're covered. So there's something that we can do about that for the immunosuppressed, the elderly, and the immunocompromised, who are not showing a healthy and protective antibody response."

@PictorLtd #pictor #PictArray #IVD #Biotech #Innovative #HumanHealth #COVID #Antibodies #AntibodyTest #ImmuneSystem

PictorDX.com

Listen to the podcast here

Dr. Tadd Lazarus is the Chief Medical Officer at Pictor, working on innovative diagnostic tests to provide answers to complicated clinical questions concerning the status of a patient's level of antibodies. From one specimen, their test can determine if the antibodies have been produced as a result of vaccinations or boosters and if the patient had the disease being tested for. Their mission is to help patients determine if they have effective antibody levels and are able to have the kind of response that will be protected them over time.

Tadd explains, "We develop innovative diagnostic solutions to enable more informed clinical decisions both in human and animal health. Specifically, we have a highly multiplexed platform that really changes the way antibodies are detected. As we know from COVID, antibodies are proteins that our body manufactures in response to infectious agents, except we detect them differently. We detect antibodies in an incredibly focused and what we call highly multiplexed manner, so that we have an incredibly sensitive and specific test. But moreover, it's able to detect multiple antibodies that the body produces for multiple infectious agents at one time. That's a very big change."

"One of the reasons why it is important to determine if vaccinations and boosters are effective is that there are antibodies that can be administered to patients intravenously if those patients are determined not to have a clinically significant antibody response to vaccinations/boosters and/or infection. And those formulations are getting tweaked now for more predominant strains, so making sure that they're covered. So there's something that we can do about that for the immunosuppressed, the elderly, and the immunocompromised, who are not showing a healthy and protective antibody response."

@PictorLtd #pictor #PictArray #IVD #Biotech #Innovative #HumanHealth #COVID #Antibodies #AntibodyTest #ImmuneSystem

PictorDX.com

Download the transcript here

David Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development.

David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But people who have been involved in the molecular data space for a while know that the integration of multiple data types and multiple data sets is very difficult, and it needs to be done in a certain context. The context in which we are incorporating the data is allowing the users to run those synthetic trials on their own or using our teams."

"One of the features that we have is the ability to run synthetic basket trials. So, take one drug, assuming the drug you want to evaluate, and run it across multiple indications in these dozens of indications. To conduct that with human subjects is prohibitive for cost and ethical reasons. And the same way, when we are conducting synthetic umbrella trials, where we're taking a specific patient population, and we are evaluating the efficacy of many different compounds in a specific patient population. Again, this would be very difficult to conduct in a clinical setting with human subjects. These are things that synthetic in silico trials allow you to do that clinical endeavors would not."

@CytoReason #DiseaseModels #ComputationalDiseaseModels #SyntheticClinicalTrials #ClinicalTrials #ComputationalBiology #DrugDevelopment #DrugDiscovery #AI #RareDiseases

CytoReason.com

Listen to the podcast here

David Harel is the Co-Founder and CEO of CytoReason, providing researchers and drug developers with a complex database and predictive computational disease models to conduct synthetic clinical trials. Their mission is to integrate all the information available on a specific disease in a particular population to support faster and more efficient drug development.

David explains, "Computational disease models are the core technology that we've developed, and it is a method to incorporate all the available information, specifically omics and molecular data, that is available in one disease, in one place, in a way that is useful. But people who have been involved in the molecular data space for a while know that the integration of multiple data types and multiple data sets is very difficult, and it needs to be done in a certain context. The context in which we are incorporating the data is allowing the users to run those synthetic trials on their own or using our teams."

"One of the features that we have is the ability to run synthetic basket trials. So, take one drug, assuming the drug you want to evaluate, and run it across multiple indications in these dozens of indications. To conduct that with human subjects is prohibitive for cost and ethical reasons. And the same way, when we are conducting synthetic umbrella trials, where we're taking a specific patient population, and we are evaluating the efficacy of many different compounds in a specific patient population. Again, this would be very difficult to conduct in a clinical setting with human subjects. These are things that synthetic in silico trials allow you to do that clinical endeavors would not."

@CytoReason #DiseaseModels #ComputationalDiseaseModels #SyntheticClinicalTrials #ClinicalTrials #ComputationalBiology #DrugDevelopment #DrugDiscovery #AI #RareDiseases

CytoReason.com

Download the transcript here